NCT04225936View on ClinicalTrials.gov

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions
Hepatic Impairment
Interventions
DRUG

BMS-986263

Single Dose

Trial Locations (1)

78215

The Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04225936 - A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment | Biotech Hunter | Biotech Hunter